An ear­ly-stage fail high­lights on­go­ing ALS drug de­vel­op­ment chal­lenges, de­spite re­cent Bio­gen OK

A Take­da part­ner re­port­ed an ear­ly-stage ALS tri­al fail­ure Tues­day morn­ing and opt­ed to dis­con­tin­ue the pro­gram en­tire­ly, serv­ing as a re­minder that de­spite two re­cent FDA ap­provals, chal­lenges re­main in tack­ling the uni­ver­sal­ly fa­tal dis­ease.

Wave Life Sci­ences said its pro­gram, dubbed WVE-004, did not show any clin­i­cal ben­e­fit when com­pared to place­bo in a sub­set of ALS pa­tients with spe­cif­ic ge­net­ic mu­ta­tions. The com­pound ad­di­tion­al­ly failed to show a ben­e­fit for pa­tients with fron­totem­po­ral de­men­tia in a sep­a­rate ben­e­fit analy­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER